Myriad Genetics Enters Oversold Territory with RSI at 29.9

Investors eye Myriad Genetics as RSI hits 29.9, signaling potential buying opportunities. The stock's recent performance indicates heavy selling is waning, making it an interesting prospect for bullish investors.

Date: 28-02-2025

AI Rating: 6

Myriad Genetics Oversold Threshold

Myriad Genetics, Inc. (MYGN) recently registered an RSI of 29.9, indicating the stock is in oversold territory, which may suggest that the current downward momentum is losing steam. This could signal potential buying opportunities for investors hoping to capitalize on turning market sentiments.

The S&P 500 ETF (SPY) has an RSI of 40.2, suggesting a comparatively healthier market sentiment. This presents a stark contrast that could attract investors looking for undervalued opportunities within the sector.

Current Stock Trading and Performance

The stock's recent trading showed a low of $11.12 per share, significantly below its 52-week high of $29.30, and slightly above its 52-week low of $9.76. The last trade registered at $11.13, highlighting a potential 52-week performance that investors may consider while deciding whether to buy, hold or sell MYGN stock.

Stocks: MYGN